Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients

Ginghină, Octav; Hudiţă, Ariana; Zaharia, Cătălin; Tsatsakis, Aristidis; Mezhuev, Ya. O.; Costache, Marieta; Gălățeanu, Bianca

doi:10.3390/ma14092440

Cited by 16 publications

(14 citation statements)

References 203 publications

(210 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several combination chemotherapeutic regimens such as FOLFIRI (folinic acid, 5-FU and IRI), XELOX/CAPOX (OXA and capecitabine) and FOLFOX (folinic acid, 5-FU and OXA) are widely used in clinical treatment for CRC[ 10 ]. However, and despite the continued efforts devoted to advance CRC chemotherapy, the prognosis of this disease is still unsatisfactory, particularly for metastatic CRC patients[ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Micelles as potential drug delivery systems for colorectal cancer treatment

Fatfat¹,

Fatfat²,

Gali‐Muhtasib³

2022

WJG

View full text Add to dashboard Cite

Despite the significant progress in cancer therapy, colorectal cancer (CRC) remains one of the most fatal malignancies worldwide. Chemotherapy is currently the mainstay therapeutic modality adopted for CRC treatment. However, the long-term effectiveness of chemotherapeutic drugs has been hampered by their low bioavailability, non-selective tumor targeting mechanisms, non-specific biodistribution associated with low drug concentrations at the tumor site and undesirable side effects. Over the last decade, there has been increasing interest in using nanotechnology-based drug delivery systems to circumvent these limitations. Various nanoparticles have been developed for delivering chemotherapeutic drugs among which polymeric micelles are attractive candidates. Polymeric micelles are biocompatible nanocarriers that can bypass the biological barriers and preferentially accumulate in tumors via the enhanced permeability and retention effect. They can be easily engineered with stimuli-responsive and tumor targeting moieties to further ensure their selective uptake by cancer cells and controlled drug release at the desirable tumor site. They have been shown to effectively improve the pharmacokinetic properties of chemotherapeutic drugs and enhance their safety profile and anticancer efficacy in different types of cancer. Given that combination therapy is the new strategy implemented in cancer therapy, polymeric micelles are suitable for multidrug delivery and allow drugs to act concurrently at the action site to achieve synergistic therapeutic outcomes. They also allow the delivery of anticancer genetic material along with chemotherapy drugs offering a novel approach for CRC therapy. Here, we highlight the properties of polymeric micelles that make them promising drug delivery systems for CRC treatment. We also review their application in CRC chemotherapy and gene therapy as well as in combination cancer chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Micelles as potential drug delivery systems for colorectal cancer treatment

Fatfat¹,

Fatfat²,

Gali‐Muhtasib³

2022

WJG

View full text Add to dashboard Cite

show abstract

“…The use of polymer nanoaggregates as carriers for drug delivery revolutionized pharmacology and opened up new possibilities for an extended circulation time, reduced toxicity, optimized release of active substances, and targeted drug delivery. [1][2][3] Polymer nanoaggregates loaded with anticancer drugs have been already successfully used for treatment of various types of cancer [4] and can eventually lead to an effective therapy for his disease which killed nearly 10 million people only in 2020. [5] Doxorubicin [6,7] and paclitaxel [8,9] are among the drugs with a broad anticancer activity, which, in some cases show a synergetic effect when used together.…”

Section: Introductionmentioning

confidence: 99%

The Synthesis and Properties of a New Carrier for Paclitaxel and Doxorubicin Based on the Amphiphilic Copolymer of N‐vinyl‐2‐pyrrolidone and Acrylic Acid

Nechaeva

Аrtyukhov

Luss

et al. 2022

Macro Chemistry & Physics

View full text Add to dashboard Cite

This paper deals with the development of polymeric nanocarriers based on amphiphilic copolymers of N-vinyl-2-pyrrolidone and acrylic acid of various molecular weights synthesized through the AIBN-initiated radical copolymerization of N-vinyl-2-pyrrolidone and acrylic acid in the presence of n-octadecyl mercaptan. The structure of the copolymers is characterized by 1 Н NMR, 13 С NMR, IR and MALDI-TOF MS spectroscopy. It is shown that the length of the hydrophilic block defines the size of the nanoaggregates while impacting the steric stabilization efficiency and the probability of the interchain hydrogen bond formation. The hydrogen bonds formation between the residues of N-vinyl-2-pyrrolidone and acrylic acid is in agreement with the reduction of the 𝜻-potential of the nanoaggregates and the critical aggregation concentrations upon increasing the molecular weight. The presence of acrylic acid residues in the amphiphilic macromolecules leads to a higher affinity for doxorubicin and slow partial release of doxorubicin bonded with the aggregates' corona, which is helpful for reducing its cardiac toxicity. Nanoaggregates with a paclitaxel-loaded hydrophobic core are obtained, showing the possibility of dual loading. The amphiphilic copolymers of N-vinyl-2-pyrrolidone and acrylic acid containing an n-octadecyl thio end group are thus promising candidates for combination cancer therapy with immobilized anti-cancer drugs, paclitaxel, and doxorubicin.

show abstract

“…Chemotherapy and surgery are the main treatment for CAC clinically. Fluorouracil and molecular targeted drugs are clinical drugs but with many adverse reactions ( Fiala et al, 2019 ; Ginghină et al, 2021 ). At the same time, there is a possibility of complications in the above treatments, and long-term medication will also reduce the compliance of patients.…”

Section: Introductionmentioning

confidence: 99%

Effects of Kalimeris indica (L.) Sch Bip on colitis-associated colorectal cancer

Wang

Li²,

Cui³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Kalimeris indica (L.) Sch Bip (K. indica) is a plant of the genus Kalimeris in Asteraceae, and its whole herb can be used as medicine for the treatment of intestinal inflammatory diseases. But the mechanism is not clear. Therefore, this study was designed to explore the mechanism of K. indica (KI) in colitis-associated colorectal cancer. The expression levels of miR-31-5p and proinflammatory factors were detected using THP-1 and Caco2 cells in vitro. KI could rescue the upregulation of miR-31-5p induced by IL-6 and TNF-α in Caco2 and THP-1 cells. In LPS-stimulated PMA-differentiated THP-1 cells, KI restored miR-31-5p expression by downregulating the expression of IL-6 and TNF-α. C57BL/6 mice were used to construct CAC model through the induction of azoxymethane/dextran sulfate sodium. The successfully established CAC mice were treated with water extract of KI through intragastric administration for 5 weeks. The result showed that KI could significantly reduce the atypical hyperplasia in colon tissue, and inhibit the expression of proinflammatory factors such as IL-6, TNF, IL-11, IL-7, etc. At the same time, KI could restore the level of miR-31-5p in mice, and therefore the downstream LATS2 to inhibit the development of CAC. These above results indicate that KI is a potentially effective herb medicine to prevent CAC.

show abstract

Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients

Cited by 16 publications

References 203 publications

Micelles as potential drug delivery systems for colorectal cancer treatment

Micelles as potential drug delivery systems for colorectal cancer treatment

The Synthesis and Properties of a New Carrier for Paclitaxel and Doxorubicin Based on the Amphiphilic Copolymer of N‐vinyl‐2‐pyrrolidone and Acrylic Acid

Effects of Kalimeris indica (L.) Sch Bip on colitis-associated colorectal cancer

Contact Info

Product

Resources

About